Pamela N Munster (Pamela Munster)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Topics

Positive Breast Cancer

Histone Deacetylase

Top Venues

Cancer research communications

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder, Anthony W Tolcher, Naoto Tada Ueno, S Lindsey Davis, Douglas W Orr, Erika Paige Hamilton, Manish R Patel, Alexander I Spira, Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R Barkund, Haiying Zhou, Aleksandr Pankov, Wayne Kong, Nadine S Jahchan, Erica L Jackson, Jessica D Sun, Melissa R Junttila, Pratik S Multani, Anneleen Daemen, Edna Chow-Maneval, Pamela N Munster
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Benedito Arruda Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Francis Powell, Bruno R Bastos, Elizabeth J Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor M Weiskittel, Hu Li, Brittany A Borden, Robert Donald Harvey, Solmaz Sahebjam, Andres Cervantes, Austin Koukol, Andrew P Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J Giles, Pamela N Munster
Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Erica S Tsang, Rahul R Aggarwal, Mallika S Dhawan, Emily K Bergsland, Edwin A Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mark M Moasser, Pamela N Munster
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer research communications 2 (7) (2022)
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, Erkut Hasan Borazanci, Manish R Sharma, Joseph M Custodio, Iulia Cristina Tudor, Hristina I Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C Sachdev
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (15) (2022)
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas R Adkins, Daniel W Bowles, Hyunseok Kang, Barbara A Burtness, Eric J Sherman, Roscoe Morton, Luc G T Morris, Zaineb Nadeem, Nora Katabi, Pamela N Munster, Gary K Schwartz
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Anniina Farkkila, Doga C Gulhan, Julia Casado, Connor A Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R Graham, Bruce J Dezube, Pamela N Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I Shapiro, Ursula A Matulonis, Peter J Park, Sampsa Hautaniemi, Peter Karl Sorger, Elizabeth M Swisher, Alan D' Andrea, Panagiotis A Konstantinopoulos
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature communications 11 (1) (2020)
Anniina Farkkila, Doga C Gulhan, Julia Casado, Connor A Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R Graham, Bruce J Dezube, Pamela N Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I Shapiro, Ursula A Matulonis, Peter J Park, Sampsa Hautaniemi, Peter Karl Sorger, Elizabeth M Swisher, Alan D' Andrea, Panagiotis A Konstantinopoulos
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature communications 11 (1) (2020)
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark M Moasser, Amy J Chien, Michelle E Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil I Daud, Michael D Rosenblum, Scott Thomas, Pamela N Munster
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature communications 11 (1) (2020)